Fluicell AB (publ) (FLUI.ST)
SEK 0.04
(0.5%)
SEK 0.04
(0.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -25.91 Million SEK | -33.48% |
| 2022 | -20.88 Million SEK | 2.04% |
| 2021 | -21.07 Million SEK | -28.36% |
| 2020 | -16.42 Million SEK | 9.34% |
| 2019 | -18.11 Million SEK | -26.03% |
| 2018 | -14.37 Million SEK | -95.14% |
| 2017 | -7.36 Million SEK | -52.23% |
| 2016 | -4.83 Million SEK | -27.63% |
| 2015 | -3.67 Million SEK | -138.4% |
| 2014 | -1.59 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -7.89 Million SEK | 2.67% |
| 2024 Q2 | -5.47 Million SEK | 35.03% |
| 2023 Q3 | -5.85 Million SEK | 14.29% |
| 2023 Q4 | -8.32 Million SEK | -42.0% |
| 2023 Q2 | -6.83 Million SEK | -32.87% |
| 2023 FY | - SEK | -33.48% |
| 2023 Q1 | -5.14 Million SEK | 21.38% |
| 2022 Q4 | -6.54 Million SEK | -160.2% |
| 2022 FY | - SEK | 2.04% |
| 2022 Q3 | -2.51 Million SEK | 63.41% |
| 2022 Q2 | -6.87 Million SEK | -45.79% |
| 2022 Q1 | -4.71 Million SEK | 15.0% |
| 2021 Q3 | -4.56 Million SEK | 20.78% |
| 2021 Q4 | -5.54 Million SEK | -21.43% |
| 2021 FY | - SEK | -28.36% |
| 2021 Q1 | -5.19 Million SEK | -11.34% |
| 2021 Q2 | -5.76 Million SEK | -11.06% |
| 2020 Q3 | -5.08 Million SEK | -64.11% |
| 2020 Q4 | -4.66 Million SEK | 8.37% |
| 2020 Q1 | -3.52 Million SEK | 36.13% |
| 2020 FY | - SEK | 9.34% |
| 2020 Q2 | -3.1 Million SEK | 12.05% |
| 2019 Q3 | -4.14 Million SEK | 6.67% |
| 2019 Q4 | -5.52 Million SEK | -33.26% |
| 2019 FY | - SEK | -26.03% |
| 2019 Q1 | -4.01 Million SEK | 13.43% |
| 2019 Q2 | -4.43 Million SEK | -10.67% |
| 2018 Q1 | -2.46 Million SEK | -16.97% |
| 2018 Q4 | -4.63 Million SEK | -36.34% |
| 2018 Q3 | -3.39 Million SEK | 11.97% |
| 2018 Q2 | -3.86 Million SEK | -56.47% |
| 2018 FY | - SEK | -95.14% |
| 2017 Q4 | -2.1 Million SEK | -1.44% |
| 2017 FY | - SEK | -52.23% |
| 2017 Q1 | -1.24 Million SEK | -25.83% |
| 2017 Q2 | -1.92 Million SEK | -54.69% |
| 2017 Q3 | -2.07 Million SEK | -7.78% |
| 2016 Q4 | -991 Thousand SEK | 0.0% |
| 2016 FY | - SEK | -27.63% |
| 2015 FY | - SEK | -138.4% |
| 2014 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 89.094% |
| Ziccum AB (publ) | -20.34 Million SEK | -27.392% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1295800.0% |
| BioArctic AB (publ) | 275.38 Million SEK | 109.41% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -1145.865% |
| Mendus AB (publ) | -97.84 Million SEK | 73.516% |
| Genovis AB (publ.) | 64.57 Million SEK | 140.132% |
| Intervacc AB (publ) | -68.98 Million SEK | 62.433% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -92.942% |
| Active Biotech AB (publ) | -43.88 Million SEK | 40.953% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 182.518% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 52.717% |
| Aptahem AB (publ) | -10 Million SEK | -158.901% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 91.837% |
| Kancera AB (publ) | -61.88 Million SEK | 58.128% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 324.383% |
| Saniona AB (publ) | -69.69 Million SEK | 62.818% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -114.095% |
| Biovica International AB (publ) | -119.5 Million SEK | 78.316% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 38.627% |
| AcouSort AB (publ) | -16.7 Million SEK | -55.146% |
| Xintela AB (publ) | -53.47 Million SEK | 51.536% |
| Abliva AB (publ) | -93.6 Million SEK | 72.316% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 91.879% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 3.245% |
| OncoZenge AB (publ) | 7.26 Million SEK | 456.647% |
| Amniotics AB (publ) | -27.14 Million SEK | 4.528% |
| 2cureX AB (publ) | -35.13 Million SEK | 26.247% |
| CombiGene AB (publ) | -35.33 Million SEK | 26.664% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -82.275% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 92.954% |
| Camurus AB (publ) | 562.54 Million SEK | 104.607% |
| Corline Biomedical AB | -1.69 Million SEK | -1432.466% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 85.049% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 30.008% |
| I-Tech AB | 30.34 Million SEK | 185.398% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 96.373% |
| Cyxone AB (publ) | -20.41 Million SEK | -26.942% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 74.706% |
| Biosergen AB | 228 Thousand SEK | 11465.789% |
| Cantargia AB (publ) | -284.31 Million SEK | 90.885% |
| NextCell Pharma AB | -40.98 Million SEK | 36.772% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 84.74% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -51.681% |
| Nanologica AB (publ) | -62.11 Million SEK | 58.283% |
| SynAct Pharma AB | -222.7 Million SEK | 88.364% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 40.918% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 8475.214% |
| LIDDS AB (publ) | -39.67 Million SEK | 34.676% |
| Lipum AB (publ) | -37.11 Million SEK | 30.187% |
| BioInvent International AB (publ) | -312.7 Million SEK | 91.713% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 61801.469% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 88.812% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -194.06% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 77.448% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -32.356% |
| Simris Alg AB (publ) | -22.36 Million SEK | -15.879% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 81.602% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 90.812% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 76.129% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -125.948% |